IDO1和IL-10在喉鳞状细胞癌组织中的表达及其与临床病理特征和预后的关系研究

Expression of IDO1 and IL-10 in laryngeal squamous cell carcinoma and their relationship with clinicopathological features and prognosis

摘要:

目的 探讨喉鳞状细胞癌（LSCC）组织中吲哚胺2，3-双加氧酶1（IDO1）和白细胞介素-10（IL-10）的表达及其与临床病理特征和预后的关系。方法 选取2015年7月—2017年7月邯郸市中心医院行喉部肿瘤切除术治疗，且术中病理确诊为LSCC的患者89例，留取LSCC组织及癌旁组织标本各89份。比较LSCC组织及癌旁组织中IDO1、IL-10的表达情况，以及LSCC患者不同临床病理特征间IDO1、IL-10表达的差异。绘制Kaplan-Meier生存曲线，比较生存时间和生存率。采用Cox多因素风险回归模型分析LSCC患者预后的影响因素。结果 LSCC组织中IDO1、IL-10表达阳性率与癌旁组织比较，差异有统计学意义（P <0.05），LSCC组织高于癌旁组织。不同TNM分期、分化程度、淋巴结转移、远处转移的LSCC患者IDO1、IL-10表达阳性率比较，差异有统计学意义（P <0.05）；不同性别、年龄、肿瘤位置的LSCC患者IDO1、IL-10表达阳性率，差异无统计学意义（P >0.05）。IDO1、IL-10阳性患者的生存时间短于IDO1、IL-10阴性患者（P <0.05）。Cox多因素风险回归模型分析结果显示，TNM分期较高［R^R=1.351（95% CI：1.055，1.730）］、分化程度较低［R^R=0.734（95% CI：0.562，0.959）］、淋巴结转移［R^R=1.448（95% CI：1.095，1.915）］、远处转移［R^R=1.246（95% CI：1.035，1.500）］、IDO1阳性表达［R^R=1.575（95% CI：1.156，2.146）］、IL-10阳性表达［R^R=1.771（95% CI：1.250，2.508）］是LSCC患者预后的影响因素（P <0.05）。结论 LSCC组织中IDO1、IL-10阳性表达率异常升高，且与患者的临床病理特征及预后密切相关，可能是导致LSCC病情加重、预后不佳的重要分子机制之一。

Abstract:

Objective To investigate the expression of indoleamine 2, 3-dioxygenase 1 (IDO1) and interleukin-10 (IL-10) in laryngeal squamous cell carcinoma (LSCC) and their relationship with clinicopathological features and prognosis.Methods From July 2015 to July 2017, 89 patients with laryngeal tumor resection and intraoperative pathological diagnosis of LSCC were selected, 89 specimens of tumor tissue and adjacent tissue were collected respectively. The expression of IDO1 and IL-10 in LSCC and paracancerous tissues were compared. The clinicopathological characteristics and survival time of patients with different expression of IDO1 and IL-10 in LSCC were compared. Cox multivariate risk regression model was used to analyze the prognostic factors of LSCC patients.Results Positive expression rates of IDO1 and IL-10 in LSCC tissues were compared with adjacent tissues, and the difference were statistically significant (P < 0.05). In LSCC patients, the positive rates of IDO1 and IL-10 expression in patients with different TNM stages, differentiation, lymph node metastasis, and distant metastasis were statistically significant (P < 0.05); there was no significant difference in the positive rates of IDO1 and IL-10 expression among patients with different gender, age and tumor location (P > 0.05). Mean survival time of IDO1 positive and IL-10 positive patients were shorter than that of IDO1 negative, IL-10 negative patients (P < 0.05). Cox multivariate risk regression model analysis results show that higher TNM stage [R^R =1.351, (95% CI: 1.055, 1.730)], lower differentiation degree [R^R = 0.734, (95% CI: 0.562, 0.959) ], lymph node metastasis [R^R = 1.448, 95% CI: 1.095, 1.915)], distant metastasis [R^R = 1.246, (95% CI: 1.035, 1.500) ], IDO1 positive expression [R^R = 1.575, (95% CI: 1.156, 2.146) ], and IL-10 positive expression [R^R = 1.771, (95% CI: 1.250, 2.508) ] were the prognostic factors of LSCC patients (P < 0.05).Conclusion The positive expression rate of IDO1 and IL-10 in LSCC tissue was increased abnormally, and it is closely related to the clinicopathological characteristics and prognosis of the patients, which may be one of the important molecular mechanisms leading to the aggravation and poor prognosis of LSCC.